Cargando…
Introducing Vernakalant into Clinical Practice
Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilita...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Radcliffe Cardiology
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434499/ https://www.ncbi.nlm.nih.gov/pubmed/30918671 http://dx.doi.org/10.15420/aer.2018.71.2 |
| _version_ | 1783406488363991040 |
|---|---|
| author | Hall, Angela JM Mitchell, Andrew RJ |
| author_facet | Hall, Angela JM Mitchell, Andrew RJ |
| author_sort | Hall, Angela JM |
| collection | PubMed |
| description | Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilitating early discharge from hospital in selected patients in place of electrical cardioversion. The authors explore the data behind vernakalant and discuss how it can be introduced into clinical practice. |
| format | Online Article Text |
| id | pubmed-6434499 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Radcliffe Cardiology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-64344992019-03-27 Introducing Vernakalant into Clinical Practice Hall, Angela JM Mitchell, Andrew RJ Arrhythm Electrophysiol Rev Drugs and Devices Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilitating early discharge from hospital in selected patients in place of electrical cardioversion. The authors explore the data behind vernakalant and discuss how it can be introduced into clinical practice. Radcliffe Cardiology 2019-03 /pmc/articles/PMC6434499/ /pubmed/30918671 http://dx.doi.org/10.15420/aer.2018.71.2 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly. |
| spellingShingle | Drugs and Devices Hall, Angela JM Mitchell, Andrew RJ Introducing Vernakalant into Clinical Practice |
| title | Introducing Vernakalant into Clinical Practice |
| title_full | Introducing Vernakalant into Clinical Practice |
| title_fullStr | Introducing Vernakalant into Clinical Practice |
| title_full_unstemmed | Introducing Vernakalant into Clinical Practice |
| title_short | Introducing Vernakalant into Clinical Practice |
| title_sort | introducing vernakalant into clinical practice |
| topic | Drugs and Devices |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434499/ https://www.ncbi.nlm.nih.gov/pubmed/30918671 http://dx.doi.org/10.15420/aer.2018.71.2 |
| work_keys_str_mv | AT hallangelajm introducingvernakalantintoclinicalpractice AT mitchellandrewrj introducingvernakalantintoclinicalpractice |